Piperazine substituted aryl benzodiazepines

1-41-41 1-63-61-41-4222 1-61-6442445656256545241-61-63 1-62-61-41-41-44 1-61-65 6 1-67 1-61-68 9 1-61 2 1-61-677278989 Described herein are compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N,...

Full description

Saved in:
Bibliographic Details
Main Authors Aicher, Thomas Daniel, Chen, Zhaogen, LeHuerou, Yvan, Martin, Fionna Mitchell, Pineiro-Nunez, Marta Maria, Rocco, Vincent Patrick, Ruley, Kevin Michael, Schaus, John Mehnert, Spinazze, Patrick Gianpietro, Tupper, David Edward
Format Patent
LanguageEnglish
Published 10.06.2008
Online AccessGet full text

Cover

Loading…
Abstract 1-41-41 1-63-61-41-4222 1-61-6442445656256545241-61-63 1-62-61-41-41-44 1-61-65 6 1-67 1-61-68 9 1-61 2 1-61-677278989 Described herein are compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, S, and O; Alk is (C) alkylene or hydroxy substituted (C) alkylene; X is oxygen or sulfur; Ris hydrogen, (C) fluroalkyl, (C) cycloalkyl, or (C) alkyl, wherein the (C) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCHCHOH, or -CN; Ris H, halogen, (C) fluoroalkyl, (C) cycloalkyl, OR, SR, NO, CN, COR, C(O)OR, CONRR, NRR, SONRR, NRCOR, NRSOR, optionally substituted aromatic, or (C) alkyl, wherein (C) alkyl is unsubstituted or substituted with a hydroxy group; Ris hydrogen (C) fluoroalkyl, (C) alkenyl, Ar, (C)alkyl-Ar, or (C) alkyl wherein (C) alkyly is unsubstituted or substituted with a phenyl; Ris hydrogen, (C) alkyl, (C) fluoroalkyl, or optionally substituted aromatic; Rand Rare independently hydrogen, (C) alkyl, or optionally substituted aromatic, Ris hydrogen, (C) alkyl, (C) fluoroalkyl, or optionally substituted aromatic; Rand Rare independently hydrogen, (C) alkyl, or optionally substituted aromatic; Ar is optionally substituted phenyl, napthyl, monocyclic heteroaromatic or bicyclic heteroaromatic; Zand Zare independently selected from hydrogen, halogen, (C) alkyl, (C) fluoroalkyl, OR, SR, NO, CN, COR, CONRR, NRR, and optionally substituted aromatic; and all salts, solvates, optical and geometric isomers, and crystalline forms thereof. Also, described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treatment of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I)
AbstractList 1-41-41 1-63-61-41-4222 1-61-6442445656256545241-61-63 1-62-61-41-41-44 1-61-65 6 1-67 1-61-68 9 1-61 2 1-61-677278989 Described herein are compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, S, and O; Alk is (C) alkylene or hydroxy substituted (C) alkylene; X is oxygen or sulfur; Ris hydrogen, (C) fluroalkyl, (C) cycloalkyl, or (C) alkyl, wherein the (C) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCHCHOH, or -CN; Ris H, halogen, (C) fluoroalkyl, (C) cycloalkyl, OR, SR, NO, CN, COR, C(O)OR, CONRR, NRR, SONRR, NRCOR, NRSOR, optionally substituted aromatic, or (C) alkyl, wherein (C) alkyl is unsubstituted or substituted with a hydroxy group; Ris hydrogen (C) fluoroalkyl, (C) alkenyl, Ar, (C)alkyl-Ar, or (C) alkyl wherein (C) alkyly is unsubstituted or substituted with a phenyl; Ris hydrogen, (C) alkyl, (C) fluoroalkyl, or optionally substituted aromatic; Rand Rare independently hydrogen, (C) alkyl, or optionally substituted aromatic, Ris hydrogen, (C) alkyl, (C) fluoroalkyl, or optionally substituted aromatic; Rand Rare independently hydrogen, (C) alkyl, or optionally substituted aromatic; Ar is optionally substituted phenyl, napthyl, monocyclic heteroaromatic or bicyclic heteroaromatic; Zand Zare independently selected from hydrogen, halogen, (C) alkyl, (C) fluoroalkyl, OR, SR, NO, CN, COR, CONRR, NRR, and optionally substituted aromatic; and all salts, solvates, optical and geometric isomers, and crystalline forms thereof. Also, described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treatment of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I)
Author Rocco, Vincent Patrick
Ruley, Kevin Michael
Spinazze, Patrick Gianpietro
LeHuerou, Yvan
Pineiro-Nunez, Marta Maria
Chen, Zhaogen
Schaus, John Mehnert
Tupper, David Edward
Aicher, Thomas Daniel
Martin, Fionna Mitchell
Author_xml – sequence: 1
  givenname: Thomas Daniel
  surname: Aicher
  fullname: Aicher, Thomas Daniel
– sequence: 2
  givenname: Zhaogen
  surname: Chen
  fullname: Chen, Zhaogen
– sequence: 3
  givenname: Yvan
  surname: LeHuerou
  fullname: LeHuerou, Yvan
– sequence: 4
  givenname: Fionna Mitchell
  surname: Martin
  fullname: Martin, Fionna Mitchell
– sequence: 5
  givenname: Marta Maria
  surname: Pineiro-Nunez
  fullname: Pineiro-Nunez, Marta Maria
– sequence: 6
  givenname: Vincent Patrick
  surname: Rocco
  fullname: Rocco, Vincent Patrick
– sequence: 7
  givenname: Kevin Michael
  surname: Ruley
  fullname: Ruley, Kevin Michael
– sequence: 8
  givenname: John Mehnert
  surname: Schaus
  fullname: Schaus, John Mehnert
– sequence: 9
  givenname: Patrick Gianpietro
  surname: Spinazze
  fullname: Spinazze, Patrick Gianpietro
– sequence: 10
  givenname: David Edward
  surname: Tupper
  fullname: Tupper, David Edward
BookMark eNrjYmDJy89L5WTQDsgsSC1KrMrMS1UoLk0qLsksKS1JTVFILKrMUUhKzavKT8lMrEotAMoX8zCwpiXmFKfyQmluBgU31xBnD93S4oLEktS8kuL49KJEEGVgbmxhYmlsYkyEEgCIBC0D
ContentType Patent
CorporateAuthor Eli Lilly and Company
CorporateAuthor_xml – name: Eli Lilly and Company
DBID EFH
DatabaseName USPTO Issued Patents
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EFH
  name: USPTO Issued Patents
  url: http://www.uspto.gov/patft/index.html
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
ExternalDocumentID 07384934
GroupedDBID EFH
ID FETCH-uspatents_grants_073849343
IEDL.DBID EFH
IngestDate Sun Mar 05 22:32:53 EST 2023
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-uspatents_grants_073849343
OpenAccessLink https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7384934
ParticipantIDs uspatents_grants_07384934
PatentNumber 7384934
PublicationCentury 2000
PublicationDate 20080610
PublicationDateYYYYMMDD 2008-06-10
PublicationDate_xml – month: 06
  year: 2008
  text: 20080610
  day: 10
PublicationDecade 2000
PublicationYear 2008
References Rasmussen et al., Preclinical Pharmacology of FMPD [6-Fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: A Potential Novel Antipsychotic with Lower Histamine H1 Receptor Affinity Than Olanzapine, The Journal of Pharmacology and Experimental Therapeutics, 2005, pp. 1265-1277, vol. 315, No. 3.
Chakrabarti et al. (4115568) 19780900
Tehim et al. (5824676) 19981000
Fu (5602121) 19970200
Chakrabarti J K et al: "Effects of Conformationally Restricted 4-Piperazinyl-10h-Thienobenzod Iazepine Neuroleptics on Central Dopamingergic and Cholinergic Systems," Journal of Medicinal Chemistry, American Chemical Society. Washington, US, vol. 25, No. 10, Oct. 1, 1982, pp. 1133-1140.
(0354781) 19900200
(WO 03082877) 20031000
(1016664) 20000700
References_xml – year: 20031000
  ident: WO 03082877
– year: 19780900
  ident: 4115568
  contributor:
    fullname: Chakrabarti et al.
– year: 19981000
  ident: 5824676
  contributor:
    fullname: Tehim et al.
– year: 19970200
  ident: 5602121
  contributor:
    fullname: Fu
– year: 20000700
  ident: 1016664
– year: 19900200
  ident: 0354781
Score 2.69992
Snippet 1-41-41 1-63-61-41-4222 1-61-6442445656256545241-61-63 1-62-61-41-41-44 1-61-65 6 1-67 1-61-68 9 1-61 2 1-61-677278989 Described herein are compounds of...
SourceID uspatents
SourceType Open Access Repository
Title Piperazine substituted aryl benzodiazepines
URI https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7384934
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfVxNS8NAEB3aImhPioqtH-zBm6wN-dgm59IQBCUHhd5Kxh2LUDchSSntr3d2I8WLXndhdpZl580wbx7APadAUTEljn5xwAWKwnfJMILSR0xIxcgYYeedn19U9hY-LaJFD7LDLMwXfyNZsS_N46ap2tKRKzm8dw8vO_FnqxForPrA1qzLQuf6YzIN4jAJwj70Y89Su-ZpNoRjNsEpm2mbX6CRnsJR7lbPoEfmHB7yz4pqp-YsGj6469FrUdS7tUAy-5Kfak-V5aFfgEjnr7NMHiwvV7VlrCy9Hw-CSxhw5U5XIPwQtVXedN2uQvuJR8R4oBIuCzGK9AhGf5oZ_7N3DScdbUFxFL2BQVtv6JaxscU7d_FvSHxvTw
link.rule.ids 230,309,786,808,891,64396
linkProvider USPTO
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfVxLT8MwDLbGQDxOIECMZw7cUGDqI2vPsKq8ph5A2q2qiUFII63aToj9epwUTVzgmkiOFSf-bNn-AM45BAqLEbH3i3xOUBS-SIYRlB5iTCpCxgg77_w4UelzcDcNpz1Il7MwH_yNZMW6NJfzpmpL11zJ7r0zvOzIny1HoLHsA59mVhY6069XIz8KYj9YgVWLsfatj5N0CzZYCAdtpm1-wUayDWuZW92BHplduMjeK6odn7No-OiuSq9FUX_NBJJZlGysBVW2E30PRDJ-uk7lUnL-VtuelXz4o4O_D33O3ekAhBegttybrt5VaC8eEjEiqJgTQwxDPYDBn2IO_9k7g_XsJskfbif3R7DZ9TAodqnH0G_rOZ0wULZ46u7gG-vkcks
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Piperazine+substituted+aryl+benzodiazepines&rft.inventor=Aicher%2C+Thomas+Daniel&rft.inventor=Chen%2C+Zhaogen&rft.inventor=LeHuerou%2C+Yvan&rft.inventor=Martin%2C+Fionna+Mitchell&rft.inventor=Pineiro-Nunez%2C+Marta+Maria&rft.inventor=Rocco%2C+Vincent+Patrick&rft.inventor=Ruley%2C+Kevin+Michael&rft.inventor=Schaus%2C+John+Mehnert&rft.inventor=Spinazze%2C+Patrick+Gianpietro&rft.inventor=Tupper%2C+David+Edward&rft.number=7384934&rft.date=2008-06-10&rft.externalDBID=n%2Fa&rft.externalDocID=07384934